PERSERIS™

Your help in reporting product concerns or adverse events plays a role in our mission to help ensure that patients have access to treatments. We monitor patient safety with appropriate tools.

For any safety-related information, product complaints, requests for medical information, or product queries, or to report an adverse event, please contact:

For North America
Email address: PatientSafetyNA@indivior.com
Toll-free phone number: + 1 877 782-6966

Click here for full Prescribing Information and BOXED WARNING for PERSERIS™ (risperidone) for extended-release injectable suspension.

PERSERIS (risperidone) for extended-release injectable suspension, for subcutaneous use.

Indication and Highlighted Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • PERSERIS is not approved for use in patients with dementia-related psychosis.

INDICATION

PERSERIS™ (risperidone) is indicated for the treatment of schizophrenia in adults.

Highlighted Safety Information

Contraindications

PERSERIS should not be administered to patients with known hypersensitivity to risperidone, paliperidone, or components of PERSERIS.

Warnings and Precautions

Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis: Increased risk of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. PERSERIS is not approved for use in patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring.

Tardive Dyskinesia: Discontinue treatment if clinically appropriate.

Metabolic Changes: Monitor for hyperglycemia, dyslipidemia and weight gain.

Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in females and males.

Orthostatic Hypotension: Monitor heart rate and blood pressure and warn patients with known cardiovascular disease or cerebrovascular disease, and risk of dehydration or syncope.

Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with a history of a clinically significant low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing PERSERIS if a clinically significant decline in WBC occurs in absence of other causative factors.

Potential for Cognitive and Motor Impairment: Use caution when operating machinery.

Seizures: Use caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Adverse Reactions

The most common adverse reactions in clinical trials (≥ 5%) and greater than twice that of placebo) were increased weight, sedation/somnolence and musculoskeletal pain. The most common injection site reactions (≥ 5%) were injection site pain and erythema (reddening of the skin).

To report SUSPECTED ADVERSE REACTIONS, contact Indivior Inc. at 1-877-782-6966 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.